What Is Dapiglutide? Definition and What Research Reports

Definition

Dapiglutide is the non-proprietary name for an investigational synthetic peptide that the published literature characterises as a dual GLP-1 and GLP-2 receptor agonist — that is, a single engineered molecule intended to activate both the glucagon-like peptide-1 receptor and the glucagon-like peptide-2 receptor. In peptide research writing, the term is used as a specific compound name rather than as a category label: when a paper says "dapiglutide," it is referring to that one dual-agonist candidate, which has appeared in murine gastrointestinal models and in early human trial work. It is a research and development-stage compound, not an approved therapeutic product.

What Class of Molecule Is It, and Where Does the Concept Come From?

Dapiglutide belongs to the broad family of peptide receptor agonists modelled on the proglucagon-derived hormones. As general biological background, GLP-1 and GLP-2 are two peptides cleaved from the same precursor protein, proglucagon, and released from enteroendocrine L cells in the intestine. GLP-1 receptor signalling is classically associated with glucose-dependent insulin release, gastric emptying and appetite pathways; GLP-2 receptor signalling is classically associated with intestinal mucosal growth and epithelial integrity. Dapiglutide's design premise, reflected in how it is named in the literature, is to combine engagement of both receptors in one peptide rather than co-administering two separate agonists.

This places it in the same general engineering tradition as other multi-agonist peptides — molecules that deliberately hit more than one incretin or gut-hormone receptor. It is distinct from single-target agents: a GLP-1-only agonist engages one receptor arm, and a GLP-2-only analogue engages the other. Dapiglutide is described across the verified literature consistently as dual GLP-1/GLP-2 (PMID 34705281).

How the Term Is Used in Research

In published papers, "dapiglutide" typically appears in three contexts:

• As a named test article in animal model work, where researchers administered it and measured gastrointestinal endpoints.
• As a mechanism example, cited when authors discuss what dual GLP-1/GLP-2 receptor engagement might do compared with single-receptor agonism.
• As a clinical candidate, in the reporting of early-phase human trials.

Because the compound is investigational, the literature base is small and recent. Readers encountering the name in a review article are most often seeing it referenced as an example of the dual-agonist design concept rather than as an established intervention.

What the Published Literature Reports

Preclinical: murine short bowel models

Two 2022 papers examined dapiglutide in mouse models of short bowel. In the first, published in the Annals of the New York Academy of Sciences, the study reported that the dual GLP-1 and GLP-2 receptor agonist dapiglutide promoted barrier function in murine short bowel (PMID 35580981). In the second, published in JPEN: Journal of Parenteral and Enteral Nutrition, researchers reported that dapiglutide attenuated intestinal insufficiency in a murine model of short bowel (PMID 34705281). Both were animal studies; findings in mice do not establish what happens in humans, and neither paper is a treatment recommendation.

Clinical: a proof-of-concept obesity trial

Dapiglutide has also been evaluated in humans. A trial published in EClinicalMedicine was described as a randomised, double-blind, placebo-controlled, parallel-group, proof-of-concept trial of dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity (PMID 41768273). "Proof-of-concept" is the operative phrase: trials at that stage are designed to test whether an effect is detectable at all and to gather early safety information, not to establish long-term efficacy, optimal regimens, or approval-grade evidence.

At-a-glance

Adverse Events: What Studies Report

Safety and tolerability information for an investigational peptide comes from the trial reports themselves. The human evidence identified here is the randomised, double-blind, placebo-controlled proof-of-concept trial in obesity (PMID 41768273); placebo-controlled designs of that type are the mechanism by which adverse events are attributed to a compound rather than to background noise. The other two verified records are murine studies of short bowel physiology (PMID 35580981, PMID 34705281), and animal work does not characterise human side-effect profiles. No adverse-event rates are stated on this page, because inventing or estimating them would misrepresent the source material; the primary reports are the appropriate place to read what was recorded.

Terms Readers Often Confuse With Dapiglutide

• GLP-1 receptor agonist — a class term covering single-target molecules. Dapiglutide is described in the literature as dual-acting, engaging GLP-1 and GLP-2 receptors (PMID 34705281).
• GLP-2 analogue — a molecule targeting only the GLP-2 receptor; this is the class associated with intestinal mucosal endpoints in short bowel research.
• Dual/triple incretin agonist — an umbrella phrase for multi-receptor peptides generally. Not all dual agonists share the same receptor pair; the specific combination matters.
• Approved medicine — dapiglutide is investigational. Appearing in a peer-reviewed trial is not the same as regulatory approval, and materials labelled "research use only" are not medicines.

Limitations of the Current Evidence

1. Small literature base. The verified record set consists of two murine studies and one proof-of-concept human trial — a narrow foundation by any standard.
2. Species gap. Barrier-function and intestinal-insufficiency findings were observed in mice (PMID 35580981, PMID 34705281), and rodent gastrointestinal models do not translate one-to-one to human disease.
3. Early-phase human data. A proof-of-concept design tests feasibility and signal, not durable outcomes (PMID 41768273).
4. Different populations. The preclinical work modelled short bowel; the human trial enrolled an obesity population. Findings in one context do not carry over to the other.

Educational Note

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, medication or investigational compound. It summarises what researchers reported in the cited publications and does not describe regimens, schedules or personal use. Dapiglutide is not an approved product, and nothing here should be read as encouragement to obtain or administer it.

References

• The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel (Annals of the New York Academy of Sciences, 2022)
• Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel (JPEN. Journal of parenteral and enteral nutrition, 2022)
• Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial (EClinicalMedicine, 2026)